As of 3:49pm ET
| -0.0682 / -2.72%|
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
|Steven C. Quay||Chairman, President & Chief Executive Officer|
|Kyle Guse||CFO, Secretary & Principal Accounting Officer|
|Janet Rose Rea||VP-Regulatory Affairs, Quality & Clinical Affairs|